オリゴヌクレオチド治療薬市場は2023年から2028年に134億4,370万米ドル、予測期間中のCAGRは19.87%で成長すると予測されます。このレポートは、全体的な分析、市場規模と予測、傾向、成長ドライバー、課題、および約25のベンダーをカバーするベンダー分析を提供します。
このレポートは、現在の市場シナリオ、最新の傾向と推進力、および全体的な市場環境に関する最新の分析を提供します。市場は、がん罹患率の増加による新規診断薬需要の増加、神経疾患に対する個別化医薬品のニーズ、オリゴヌクレオチド治療薬の入手可能性の増加などが牽引しています。
本調査では、DNAシーケンシングの進歩が今後数年間のオリゴヌクレオチド治療薬市場成長を牽引する主要因の1つとして、マイクロ流体技術の採用を増加させていることを指摘しています。また、新興経済諸国における高い市場成長ポテンシャルと、疾患評価における人工知能の採用拡大が、市場の大きな需要につながります。
また、本レポートには、市場の成長に影響を与える今後の傾向と課題に関する情報が含まれています。これは、企業が今後のすべての成長機会を戦略化し、活用するのに役立ちます。
この調査は、業界の主要参加者からの意見を含む一次情報と二次情報を客観的に組み合わせて実施されました。このレポートには、主要ベンダーの分析に加えて、包括的な市場とベンダーの状況が含まれています。
このレポートは、利益、価格設定、競争、プロモーションなどの主要なパラメーターの分析による複数のソースからのデータの調査、合成、合計により、市場の詳細な全体像を提示します。業界の主要な影響力を持つ企業を特定することで、さまざまな市場の側面を示します。提示されたデータは包括的で信頼性が高く、一次および二次の両方にわたる広範な研究の結果です。市場調査レポートは、正確な市場の成長を予測するための定性的および定量的調査を使用した、完全な競争状況と詳細なベンダー選択方法論および分析を提供します。
目次
Table of Contents
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
4 Historic Market Size
4.1 Global oligonucleotide therapeutics market 2018 - 2022
4.2 Type Segment Analysis 2018 - 2022
4.3 Application Segment Analysis 2018 - 2022
4.4 Geography Segment Analysis 2018 - 2022
4.5 Country Segment Analysis 2018 - 2022
5 Five Forces Analysis
5.1 Five forces summary
5.2 Bargaining power of buyers
5.3 Bargaining power of suppliers
5.4 Threat of new entrants
5.5 Threat of substitutes
5.6 Threat of rivalry
5.7 Market condition
6 Market Segmentation by Type
6.1 Market segments
6.2 Comparison by Type
6.3 Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028
6.4 RNA interference (RNAi) - Market size and forecast 2023-2028
6.5 Aptamers and others - Market size and forecast 2023-2028
6.6 Market opportunity by Type
7 Market Segmentation by Application
7.1 Market segments
7.2 Comparison by Application
7.3 Neurological - Market size and forecast 2023-2028
7.4 Cancer - Market size and forecast 2023-2028
7.5 Infectious diseases and others - Market size and forecast 2023-2028
7.6 Market opportunity by Application
8 Customer Landscape
8.1 Customer landscape overview
9 Geographic Landscape
9.1 Geographic segmentation
9.2 Geographic comparison
9.3 North America - Market size and forecast 2023-2028
9.4 Europe - Market size and forecast 2023-2028
9.5 Asia - Market size and forecast 2023-2028
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
9.7 US - Market size and forecast 2023-2028
9.8 UK - Market size and forecast 2023-2028
9.9 Germany - Market size and forecast 2023-2028
9.10 Canada - Market size and forecast 2023-2028
9.11 Japan - Market size and forecast 2023-2028
9.12 Market opportunity By Geographical Landscape
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
11.3 Landscape disruption
11.4 Industry risks
12 Vendor Analysis
12.1 Vendors covered
12.2 Market positioning of vendors
12.3 Agilent Technologies Inc.
12.4 Alnylam Pharmaceuticals Inc.
12.5 Biogen Inc.
12.6 CSL Ltd.
12.7 GlaxoSmithKline Plc
12.8 Ionis Pharmaceuticals Inc.
12.9 Maravai LifeSciences Holdings Inc.
12.10 Merck KGaA
12.11 Nippon Shinyaku Co. Ltd.
12.12 Novartis AG
12.13 Pfizer Inc.
12.14 Sarepta Therapeutics Inc.
12.15 Thermo Fisher Scientific Inc.
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
13.3 Currency conversion rates for US$
13.4 Research methodology
13.5 List of abbreviations
Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Type
Exhibits6: Executive Summary - Chart on Market Segmentation by Application
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size - Data Table on global oligonucleotide therapeutics market 2018 - 2022 ($ million)
Exhibits19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
Exhibits20: Historic Market Size - Application Segment 2018 - 2022 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits23: Five forces analysis - Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition - Five forces 2023 and 2028
Exhibits30: Chart on Type - Market share 2023-2028 (%)
Exhibits31: Data Table on Type - Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Antisense oligonucleotides (ASOs) - Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Antisense oligonucleotides (ASOs) - Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on RNA interference (RNAi) - Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on RNA interference (RNAi) - Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on RNA interference (RNAi) - Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on RNA interference (RNAi) - Year-over-year growth 2023-2028 (%)
Exhibits42: Chart on Aptamers and others - Market size and forecast 2023-2028 ($ million)
Exhibits43: Data Table on Aptamers and others - Market size and forecast 2023-2028 ($ million)
Exhibits44: Chart on Aptamers and others - Year-over-year growth 2023-2028 (%)
Exhibits45: Data Table on Aptamers and others - Year-over-year growth 2023-2028 (%)
Exhibits46: Market opportunity by Type ($ million)
Exhibits47: Data Table on Market opportunity by Type ($ million)
Exhibits48: Chart on Application - Market share 2023-2028 (%)
Exhibits49: Data Table on Application - Market share 2023-2028 (%)
Exhibits50: Chart on Comparison by Application
Exhibits51: Data Table on Comparison by Application
Exhibits52: Chart on Neurological - Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Neurological - Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Neurological - Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Neurological - Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Cancer - Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Cancer - Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Cancer - Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Cancer - Year-over-year growth 2023-2028 (%)
Exhibits60: Chart on Infectious diseases and others - Market size and forecast 2023-2028 ($ million)
Exhibits61: Data Table on Infectious diseases and others - Market size and forecast 2023-2028 ($ million)
Exhibits62: Chart on Infectious diseases and others - Year-over-year growth 2023-2028 (%)
Exhibits63: Data Table on Infectious diseases and others - Year-over-year growth 2023-2028 (%)
Exhibits64: Market opportunity by Application ($ million)
Exhibits65: Data Table on Market opportunity by Application ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits103: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits104: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits107: Market opportunity By Geographical Landscape ($ million)
Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits109: Impact of drivers and challenges in 2023 and 2028
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: Agilent Technologies Inc. - Overview
Exhibits116: Agilent Technologies Inc. - Business segments
Exhibits117: Agilent Technologies Inc. - Key news
Exhibits118: Agilent Technologies Inc. - Key offerings
Exhibits119: Agilent Technologies Inc. - Segment focus
Exhibits120: Alnylam Pharmaceuticals Inc. - Overview
Exhibits121: Alnylam Pharmaceuticals Inc. - Product / Service
Exhibits122: Alnylam Pharmaceuticals Inc. - Key offerings
Exhibits123: Biogen Inc. - Overview
Exhibits124: Biogen Inc. - Product / Service
Exhibits125: Biogen Inc. - Key news
Exhibits126: Biogen Inc. - Key offerings
Exhibits127: CSL Ltd. - Overview
Exhibits128: CSL Ltd. - Business segments
Exhibits129: CSL Ltd. - Key news
Exhibits130: CSL Ltd. - Key offerings
Exhibits131: CSL Ltd. - Segment focus
Exhibits132: GlaxoSmithKline Plc - Overview
Exhibits133: GlaxoSmithKline Plc - Business segments
Exhibits134: GlaxoSmithKline Plc - Key news
Exhibits135: GlaxoSmithKline Plc - Key offerings
Exhibits136: GlaxoSmithKline Plc - Segment focus
Exhibits137: Ionis Pharmaceuticals Inc. - Overview
Exhibits138: Ionis Pharmaceuticals Inc. - Business segments
Exhibits139: Ionis Pharmaceuticals Inc. - Key news
Exhibits140: Ionis Pharmaceuticals Inc. - Key offerings
Exhibits141: Ionis Pharmaceuticals Inc. - Segment focus
Exhibits142: Maravai LifeSciences Holdings Inc. - Overview
Exhibits143: Maravai LifeSciences Holdings Inc. - Business segments
Exhibits144: Maravai LifeSciences Holdings Inc. - Key offerings
Exhibits145: Maravai LifeSciences Holdings Inc. - Segment focus
Exhibits146: Merck KGaA - Overview
Exhibits147: Merck KGaA - Business segments
Exhibits148: Merck KGaA - Key news
Exhibits149: Merck KGaA - Key offerings
Exhibits150: Merck KGaA - Segment focus
Exhibits151: Nippon Shinyaku Co. Ltd. - Overview
Exhibits152: Nippon Shinyaku Co. Ltd. - Business segments
Exhibits153: Nippon Shinyaku Co. Ltd. - Key offerings
Exhibits154: Nippon Shinyaku Co. Ltd. - Segment focus
Exhibits155: Novartis AG - Overview
Exhibits156: Novartis AG - Business segments
Exhibits157: Novartis AG - Key news
Exhibits158: Novartis AG - Key offerings
Exhibits159: Novartis AG - Segment focus
Exhibits160: Pfizer Inc. - Overview
Exhibits161: Pfizer Inc. - Product / Service
Exhibits162: Pfizer Inc. - Key news
Exhibits163: Pfizer Inc. - Key offerings
Exhibits164: Sarepta Therapeutics Inc. - Overview
Exhibits165: Sarepta Therapeutics Inc. - Product / Service
Exhibits166: Sarepta Therapeutics Inc. - Key offerings
Exhibits167: Thermo Fisher Scientific Inc. - Overview
Exhibits168: Thermo Fisher Scientific Inc. - Business segments
Exhibits169: Thermo Fisher Scientific Inc. - Key news
Exhibits170: Thermo Fisher Scientific Inc. - Key offerings
Exhibits171: Thermo Fisher Scientific Inc. - Segment focus
Exhibits172: Inclusions checklist
Exhibits173: Exclusions checklist
Exhibits174: Currency conversion rates for US$
Exhibits175: Research methodology
Exhibits176: Validation techniques employed for market sizing
Exhibits177: Information sources
Exhibits178: List of abbreviations
